SoftBank Group Launches AI Healthcare Venture with Tempus AI

Supraja

SoftBank Group (9984.T), a leading technology investor, has initiated a partnership with Tempus AI (TEM.O) for healthcare transformation using artificial intelligence (AI) to suggest treatment options.

Masayoshi Son, the CEO of SoftBank, discussed this collaboration during a meeting in Tokyo. This announcement marks the latest in a series of AI-related investments by SoftBank, as the company has ramped up its investment efforts following a period of slower activity.

SoftBank contributed approximately US$200 million to Tempus during its series G funding phase in April, and Tempus went public on the Nasdaq in June.

Tempus offers genomic testing services and provides AI-driven advice on treatments and recommendations for clinical trials, utilizing a vast collection of patients' medical records.

The companies plan to introduce this service in Japan, aiming to be the sole provider of such services outside the U.S., Son mentioned during the briefing.

Read More Stories